Navigation Links
Antiviral Drugs Should Be Used Cautiously to Fight Flu, U.S. Says
Date:9/8/2009

Most people won't need medicines like Tamiflu or Relenza, according to CDC

TUESDAY, Sept. 8 (HealthDay News) -- Antiviral medications such as Tamiflu and Relenza, which are effective in treating the H1N1 swine flu, should be taken only by people hospitalized with the flu or those at high risk for complications from the disease, U.S. health officials said Tuesday.

Those at risk include people with underlying health conditions, such as asthma or diabetes, as well as the very young, the elderly, and pregnant women, officials said.

Because the H1N1 swine flu remains mild for the vast majority of people who get it, most people won't need these medications at all, according to new guidelines for antiviral drug use issued by the U.S. Centers for Disease Control and Prevention.

"Antiviral medicines are a critical part of our tool kit in countering influenza, both the 2009 H1N1 influenza virus and seasonal flu strains," Dr. Anne Schuchat, director of CDC's National Center for Immunization and Respiratory Diseases, said during an afternoon news conference.

But, Schuchat added, "most children, adolescents and adults who have influenza-like illness do not need antiviral medicine."

One reason why: If too many people take antiviral medicines it could increase the risk that the virus would become resistant to these drugs, Schuchat said.

"We have seen a bit of antiviral resistance already with the 2009 H1N1 strain, and we hope this won't take off," she said. "A critical feature is to use these antivirals very carefully so they can have benefit and not lead to problems."

Because most people who get the flu -- whether H1N1 swine flu or seasonal flu -- will not be tested to see what type of flu they have, the new guidelines are based on symptoms, not a particular flu strain, Schuchat said.

"A key point of the antiviral guidance is that hospitalized patients who are suspected to have influenza need prompt treatment with antiviral medicines," she said. "That can be a very important way to reduce the severity of illness. We don't want providers to wait until test results are available, but we want them to start antivirals when you suspect influenza."

The new guidelines also recommend that, when high-risk people have been in contact with someone who has the H1N1 swine flu, doctors should wait to see if flu symptoms develop before starting treatment with antivirals.

"Instead of starting antivirals, we give providers an option we call 'watchful waiting,' and wait and see if fever develops," Schuchat said. "And, when fever or respiratory problems develop, give antivirals then."

Another key to the best use of antivirals in people at risk for complications is to start the drugs as soon as flu symptoms appear, Schuchat said.

She stressed, however, that the new guidelines leave room for judgment and discretion on the part of doctors. "Every patient is different, and we want clinicians to have that opportunity to customize care for each patient," she said.

The recommendations include:

  • Treatment with antivirals is recommended for people at higher risk for complications. These include children younger than 5 years old, adults 65 and older, pregnant women, people with chronic medical or immunosuppressive conditions, such as patients on chemotherapy, and people younger than 19 years of age who are receiving long-term aspirin therapy.
  • Treatment should not wait for lab tests because testing can delay treatment and a negative rapid test for flu does not rule out influenza.
  • For some high-risk patients, doctors may choose to give them antiviral prescriptions that can be filled should symptoms appear.

Schuchat noted that cases of H1N1 swine flu -- now the predominant flu strain in the United States -- have already started to increase, especially in southeastern states. "The H1N1 flu never went away this summer," she said. "It is not surprising that we are seeing this uptick in cases."

The good news is that the H1N1 virus still hasn't mutated into a more dangerous form, which means that the vaccine currently being tested should be a good match, she said.

The first 45 million doses of the vaccine are expected by mid-October.

More information

For more on H1N1 swine flu, visit Flu.gov.



SOURCE: Sept. 8, 2009, teleconference with Anne Schuchat, M.D., director, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, Atlanta


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Antiviral Wont Improve Bells Palsy Outcome
2. Antivirals reduce deaths from flu in hospitalized patients
3. Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop
4. Antiviral therapy helps children at risk for post-transplant lymphoproliferative disease
5. Doctor Recommends New Powerful Natural Antiviral Against the Flu
6. Common Flu Strain Resistant to Popular Antiviral Drug
7. eFoodSafety Enters Research Agreement with University of Minnesota to Test New Food-Grade Antiviral for Swine Influenza Virus
8. Liver transplant recipients with hepatitis B may need lifelong antiviral treatment
9. Obio Pharmaceutical Announced New Antiviral Drug Discovery to Combat Influenza Virus
10. Do patients at risk for B-cell malignancy need antiviral treatment?
11. Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... ... 2016 , ... Georgia State University College of Law is ... Answering to the increasing demand for curricular specializations, the Certificate in Intellectual Property ... land use law. ,  , “The demand for lawyers with specific knowledge in ...
(Date:5/26/2016)... ... 2016 , ... There are nearly 14.5 million people living with and beyond ... Sunday, June 5, 2016, communities around the world will gather to recognize these cancer ... Cancer Survivors Day® is an annual worldwide Celebration of Life that is held on ...
(Date:5/26/2016)... ... ... effort to provide hair restoration information to the widest possible audience, Dr. Parsa Mohebi is ... the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making all of ... Mohebi says, “The positive response to the Snapchat videos we started last month has been ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
(Date:5/25/2016)... IRVINE, Calif. , May 25, 2016 /PRNewswire/ ... of testing for their new reference materials that ... workflows from sample collection to analyses. The rapid ... the demand for researchers to have standard methods ... data being generated. Biases inherently exist at every ...
Breaking Medicine Technology: